Stockscreener 앱 받기
72.30
1.15%
0.82
시간 외 거래:
72.00
-0.30
-0.41%
전일 마감가:
$71.48
열려 있는:
$71.61
하루 거래량:
666.61K
Relative Volume:
0.52
시가총액:
$7.67B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
57.38
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
+4.78%
1개월 성능:
+6.07%
6개월 성능:
+6.31%
1년 성능:
+112.21%
1일 변동 폭
$71.59
$73.08
1주일 범위
$66.46
$73.08
52주 변동 폭
$33.34
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
72.30 | 7.43B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Corcept's Q2 Demand Grows 60% Penetrating Large Type 2 Diabetes Market Early (NASDAQ:CORT) - Seeking Alpha
Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension - TipRanks
Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study - TipRanks
Why Corcept Therapeutics' (NASDAQ:CORT) Earnings Are Better Than They Seem - Yahoo Finance
Assessing the Impact of Pre-Scheduled Insider Sales at Corcept Therapeutics on Investor Confidence and Market Dynamics - AInvest
Corcept Therapeutics Insider Sold Shares Worth $2,373,237, According to a Recent SEC Filing - MarketScreener
Corcept Therapeutics Insider Sold Shares Worth $393,128, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics officer Lyon sells $393k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock By Investing.com - Investing.com India
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock - Investing.com
Corcept Therapeutics CEO Guyer William Buys, Sells Shares on August 5, 2025. - AInvest
Cushings Syndrome Market Exclusive Report with Detailed Study - openPR.com
How does Corcept Therapeutics Incorporated compare to its industry peersLightning-fast growth - Jammu Links News
How strong is Corcept Therapeutics Incorporated company’s balance sheetTriple-digit wealth increases - Jammu Links News
How volatile is Corcept Therapeutics Incorporated stock compared to the marketGet professional advice for market timing - Jammu Links News
Corcept Therapeutics Analyst Rating Update: Canaccord Genuity Maintains 'Buy' Rating with Lowered Price Target to 137.00 USD - AInvest
What catalysts could drive Corcept Therapeutics Incorporated stock higher in 2025Dynamic profit opportunities - Jammu Links News
Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFastest return on investment - Jammu Links News
What are the latest earnings results for Corcept Therapeutics IncorporatedInvest smarter with daily stock recommendations - Jammu Links News
What analysts say about Corcept Therapeutics Incorporated stockRealize exceptional returns through smart trading - Jammu Links News
CORT's Q2 Earnings Beat and Pipeline Momentum: A Case for Revisiting the Downside as a Buy Opportunity - AInvest
When is Corcept Therapeutics Incorporated stock expected to show significant growthTremendous financial leverage - Jammu Links News
Corcept Therapeutics (CORT): A High-Conviction Buy Amidst Breakthroughs in Cortisol-Modulating Therapies - AInvest
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript - Insider Monkey
Corcept Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Published on: 2025-08-02 05:25:16 - metal.it
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates - MSN
Corcept Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Corcept Therapeutics Incorporated Recovery Hinges on Volume BreakoutNews Based Entry Opportunity Alerts Detected - metal.it
Corcept Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $121 to $145 - 富途牛牛
Corcept Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Declines 1% - AInvest
Corcept Faces Growing Pains As Earnings Miss The Mark - Finimize
Corcept Therapeutics Q2 CY2025: Revenue Misses, Earnings BeatNews and Statistics - IndexBox
Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches - TipRanks
Corcept: Q2 Earnings Snapshot - Connecticut Post
Earnings call transcript: Corcept Therapeutics Q2 2025 earnings beat expectations By Investing.com - Investing.com Canada
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets - Yahoo Finance
Corcept Therapeutics Reports Strong Q2 Earnings, Surpassing Analyst ExpectationsNews and Statistics - IndexBox
Corcept Therapeutics falls as revenue guidance disappoints investors By Investing.com - Investing.com Canada
CORCEPT THERAPEUTICS INC SEC 10-Q Report - TradingView
Corcept Earnings: Record Patient Growth Drives 19% Revenue Jump, Pipeline Scores Multiple Wins - Stock Titan
Insiders Favor These 3 High Growth Companies - Yahoo.co
Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome - TipRanks
What To Expect From Corcept’s (CORT) Q2 Earnings - TradingView
Corcept Therapeutics' Q2 Earnings: A Critical Inflection Point for Growth and Innovation - AInvest
Corcept Therapeutics Inc expected to post earnings of 19 cents a shareEarnings Preview - TradingView
Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension - The Globe and Mail
Technical Charts Suggest Momentum Shift in Corcept Therapeutics IncorporatedSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Corcept Therapeutics CORT 2025Q2 Earnings Preview Upside Ahead on Hypercortisolism Market Expansion - AInvest
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):